Con continued treatment Antimetabolites for Cancer research with 24-month study, the detection of BCR-ABL mutations Was similar between dasatinib and imatinib, but the T315I mutation was detected mainly in the Dasa-tinib group T315I was not detected in the imatinib group . It is important to note that in the study DASISION, BCR ABL mutation analysis according to the protocol was done, only patients receiving treatment study discontinued for any reason, can, for patients, select the specific developmental w, Dasatinib-resistant mutations. At that time there insufficientwith imatinib 800 mg 400 mg monotherapy compared. Intensified therapy in de novo leukemia Chemistry study found that patients who were able to maintain an average dose of 600 mg per day may need during the first 6 months of study hours Here rates of MMR had 12 months and 24 compared to those with doses of 600 mg of imatinib below average / d. However, multicenter Phase 3 tyrosine kinase inhibitor optimization and selectivity of t Study mg in the first-line standard-dose imatinib 400 / day compared to 800 in comparison mg / d, there was no significant difference was found in the rates , a rate completely ndigen cytogenetic response cumulative ROR, EFS, OS, or PFS between the two doses. Although some studies have better results with high-dose imatinib suggested that h Higher doses are less well tolerated. In the study, TOPS, for example, dropout rates were associated AE 8% versus 5% in the imatinib 800 mg and 400 mg of imatinib, respectively. 4.2. The combination of treatments by combining imatinib with other agents was also investigated. The four arms STI571 prospective randomized study, an open, randomized Phase 3 trials in patients naive to CH5424802 1256580-46-7 treatment with ï mg CP CML, imatinib-com 400 mg / d compared with imatinib 600 / d in comparison, imatinib 400 mg / d plus cytarabine and imatinib 400 mg / d, plus PEG-IFN alfa-2a. After 18 months, the rate of 42% MMR with imatinib 400 mg, 62% with imatinib / PEG-IFN, 50% with imatinib 600 mg, and 53% with imatinib / cytarabine. Although the combination of imatinib / PEG-IFN appeared to be most effective, the H half Of the patients in this treatment arm broke within 1 year due to toxicity of t. CML in the German study, the cumulative incidence of CCR and MMR h Ago versus 800 mg imatinib treatment combination with imatinib 400 mg and IFN. In H Hematology Oncology voor Nederland Volwassenen 51 study patients were newly diagnosed with CML was again U increasing doses of imatinib, cytarabine 200 mg/m2 and 1000 mg/m2 on days 1 to 7 Five-year cumulative rates of completely Ndigen cytogenetic response were 89% MMR and CMR, 71% and 53% and an h Here dosage of imatinib and cytarabine for the start of treatment were associated with increased Hten the WRC. Further studies are underway to combine and efficacy of combination therapy treatment strategies aufzukl Ren. W While studies have been evaluated mainly combinations with imatinib should be to explore future Diosmetin studies tinib and dasatinib combinations increasingly Nilo. 4.3. Prognostic significance of early response Another strategy for newly diagnosed CML patients is to use the dd response to treatment, to determine the prognosis of patients. Studies have evaluated the early response to imatinib as Pr Predictor for positive results. Achieve a minor cytogenetic response, big e cytogeneticresponse, or the best answer to the completely Ndigen or partial cytogenetic response Cyr at 3 months, 6 months and 12 months.